"Global Genomic Cancer Testing Market Overview:
Global Genomic Cancer Testing Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Genomic Cancer Testing Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Genomic Cancer Testing involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Genomic Cancer Testing Market:
The Genomic Cancer Testing Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Genomic Cancer Testing Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Genomic Cancer Testing Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Genomic Cancer Testing market has been segmented into:
Genomic Profiling Tests
Liquid Biopsy Tests
Companion Diagnostic Tests
Pharmacogenomic Tests
Hereditary Cancer Tests
Other specialized genomic tests
By Application, Genomic Cancer Testing market has been segmented into:
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Melanoma
Leukemia
Lymphoma
Other specific cancer types
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Genomic Cancer Testing market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Genomic Cancer Testing market.
Top Key Players Covered in Genomic Cancer Testing market are:
Illuminainc.
Thermo Fisher Scientificinc.
Qiagen N.V.
F. Hoffmann-La Roche Ltd.
Foundation Medicineinc. (Roche)
Invitae Corporation
NeoGenomics Laboratoriesinc.
Myriad Geneticsinc.
Genomic Healthinc. (Exact Sciences Corporation)
Caris Life Sciences
ArcherDXinc. (Invitae Corporation)
Guardant Healthinc.
Personal Genome Diagnostics Inc.
Bioceptinc.
Tempus Labsinc.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Genomic Cancer Testing Market by Type
4.1 Genomic Cancer Testing Market Snapshot and Growth Engine
4.2 Genomic Cancer Testing Market Overview
4.3 Genomic Profiling Tests
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Genomic Profiling Tests: Geographic Segmentation Analysis
4.4 Liquid Biopsy Tests
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Liquid Biopsy Tests: Geographic Segmentation Analysis
4.5 Companion Diagnostic Tests
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Companion Diagnostic Tests: Geographic Segmentation Analysis
4.6 Pharmacogenomic Tests
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Pharmacogenomic Tests: Geographic Segmentation Analysis
4.7 Hereditary Cancer Tests
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Hereditary Cancer Tests: Geographic Segmentation Analysis
4.8 Other specialized genomic tests
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Other specialized genomic tests: Geographic Segmentation Analysis
Chapter 5: Genomic Cancer Testing Market by Application
5.1 Genomic Cancer Testing Market Snapshot and Growth Engine
5.2 Genomic Cancer Testing Market Overview
5.3 Breast Cancer
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Breast Cancer: Geographic Segmentation Analysis
5.4 Lung Cancer
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Lung Cancer: Geographic Segmentation Analysis
5.5 Colorectal Cancer
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Colorectal Cancer: Geographic Segmentation Analysis
5.6 Prostate Cancer
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Prostate Cancer: Geographic Segmentation Analysis
5.7 Ovarian Cancer
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Ovarian Cancer: Geographic Segmentation Analysis
5.8 Melanoma
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Melanoma: Geographic Segmentation Analysis
5.9 Leukemia
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Leukemia: Geographic Segmentation Analysis
5.10 Lymphoma
5.10.1 Introduction and Market Overview
5.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.10.3 Key Market Trends, Growth Factors and Opportunities
5.10.4 Lymphoma: Geographic Segmentation Analysis
5.11 Other specific cancer types
5.11.1 Introduction and Market Overview
5.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.11.3 Key Market Trends, Growth Factors and Opportunities
5.11.4 Other specific cancer types: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Genomic Cancer Testing Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ILLUMINAINC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 THERMO FISHER SCIENTIFICINC.
6.4 QIAGEN N.V.
6.5 F. HOFFMANN-LA ROCHE LTD.
6.6 FOUNDATION MEDICINEINC. (ROCHE)
6.7 INVITAE CORPORATION
6.8 NEOGENOMICS LABORATORIESINC.
6.9 MYRIAD GENETICSINC.
6.10 GENOMIC HEALTHINC. (EXACT SCIENCES CORPORATION)
6.11 CARIS LIFE SCIENCES
6.12 ARCHERDXINC. (INVITAE CORPORATION)
6.13 GUARDANT HEALTHINC.
6.14 PERSONAL GENOME DIAGNOSTICS INC.
6.15 BIOCEPTINC.
6.16 TEMPUS LABSINC.
Chapter 7: Global Genomic Cancer Testing Market By Region
7.1 Overview
7.2. North America Genomic Cancer Testing Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Genomic Profiling Tests
7.2.4.2 Liquid Biopsy Tests
7.2.4.3 Companion Diagnostic Tests
7.2.4.4 Pharmacogenomic Tests
7.2.4.5 Hereditary Cancer Tests
7.2.4.6 Other specialized genomic tests
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Breast Cancer
7.2.5.2 Lung Cancer
7.2.5.3 Colorectal Cancer
7.2.5.4 Prostate Cancer
7.2.5.5 Ovarian Cancer
7.2.5.6 Melanoma
7.2.5.7 Leukemia
7.2.5.8 Lymphoma
7.2.5.9 Other specific cancer types
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Genomic Cancer Testing Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Genomic Profiling Tests
7.3.4.2 Liquid Biopsy Tests
7.3.4.3 Companion Diagnostic Tests
7.3.4.4 Pharmacogenomic Tests
7.3.4.5 Hereditary Cancer Tests
7.3.4.6 Other specialized genomic tests
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Breast Cancer
7.3.5.2 Lung Cancer
7.3.5.3 Colorectal Cancer
7.3.5.4 Prostate Cancer
7.3.5.5 Ovarian Cancer
7.3.5.6 Melanoma
7.3.5.7 Leukemia
7.3.5.8 Lymphoma
7.3.5.9 Other specific cancer types
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Genomic Cancer Testing Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Genomic Profiling Tests
7.4.4.2 Liquid Biopsy Tests
7.4.4.3 Companion Diagnostic Tests
7.4.4.4 Pharmacogenomic Tests
7.4.4.5 Hereditary Cancer Tests
7.4.4.6 Other specialized genomic tests
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Breast Cancer
7.4.5.2 Lung Cancer
7.4.5.3 Colorectal Cancer
7.4.5.4 Prostate Cancer
7.4.5.5 Ovarian Cancer
7.4.5.6 Melanoma
7.4.5.7 Leukemia
7.4.5.8 Lymphoma
7.4.5.9 Other specific cancer types
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Genomic Cancer Testing Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Genomic Profiling Tests
7.5.4.2 Liquid Biopsy Tests
7.5.4.3 Companion Diagnostic Tests
7.5.4.4 Pharmacogenomic Tests
7.5.4.5 Hereditary Cancer Tests
7.5.4.6 Other specialized genomic tests
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Breast Cancer
7.5.5.2 Lung Cancer
7.5.5.3 Colorectal Cancer
7.5.5.4 Prostate Cancer
7.5.5.5 Ovarian Cancer
7.5.5.6 Melanoma
7.5.5.7 Leukemia
7.5.5.8 Lymphoma
7.5.5.9 Other specific cancer types
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Genomic Cancer Testing Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Genomic Profiling Tests
7.6.4.2 Liquid Biopsy Tests
7.6.4.3 Companion Diagnostic Tests
7.6.4.4 Pharmacogenomic Tests
7.6.4.5 Hereditary Cancer Tests
7.6.4.6 Other specialized genomic tests
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Breast Cancer
7.6.5.2 Lung Cancer
7.6.5.3 Colorectal Cancer
7.6.5.4 Prostate Cancer
7.6.5.5 Ovarian Cancer
7.6.5.6 Melanoma
7.6.5.7 Leukemia
7.6.5.8 Lymphoma
7.6.5.9 Other specific cancer types
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Genomic Cancer Testing Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Genomic Profiling Tests
7.7.4.2 Liquid Biopsy Tests
7.7.4.3 Companion Diagnostic Tests
7.7.4.4 Pharmacogenomic Tests
7.7.4.5 Hereditary Cancer Tests
7.7.4.6 Other specialized genomic tests
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Breast Cancer
7.7.5.2 Lung Cancer
7.7.5.3 Colorectal Cancer
7.7.5.4 Prostate Cancer
7.7.5.5 Ovarian Cancer
7.7.5.6 Melanoma
7.7.5.7 Leukemia
7.7.5.8 Lymphoma
7.7.5.9 Other specific cancer types
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Genomic Cancer Testing Scope:
|
Report Data
|
Genomic Cancer Testing Market
|
|
Genomic Cancer Testing Market Size in 2025
|
USD XX million
|
|
Genomic Cancer Testing CAGR 2025 - 2032
|
XX%
|
|
Genomic Cancer Testing Base Year
|
2024
|
|
Genomic Cancer Testing Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Illuminainc., Thermo Fisher Scientificinc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Foundation Medicineinc. (Roche), Invitae Corporation, NeoGenomics Laboratoriesinc., Myriad Geneticsinc., Genomic Healthinc. (Exact Sciences Corporation), Caris Life Sciences, ArcherDXinc. (Invitae Corporation), Guardant Healthinc., Personal Genome Diagnostics Inc., Bioceptinc., Tempus Labsinc..
|
|
Key Segments
|
By Type
Genomic Profiling Tests
Liquid Biopsy Tests
Companion Diagnostic Tests
Pharmacogenomic Tests
Hereditary Cancer Tests
Other specialized genomic tests
By Applications
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Melanoma
Leukemia
Lymphoma
Other specific cancer types
|
